Thermo Fisher Scientific has delivered solid gains in recent years, and the question now is whether the current US$704.15 share price lines up with the cash flows its business produces. With investors watching a stream of product launches and market reports linked to cell and gene therapy, bioprocessing and diagnostics, the focus naturally shifts to what those moves could mean for the stock's underlying cash generation.
- Over the past 3 years the stock has returned 61.2%, which puts meaningful expectations on how much cash the business can reliably produce over time.
- Recent product launches in areas like bioprocessing reagents and proteomic biomarker analytics, along with expansion in cell and gene therapy services, may support expectations for future cash flows and the timing of those inflows.
- What if you looked at Thermo Fisher Scientific through its earnings instead? See why Thermo Fisher Scientific's 36.8x P/E tells a different valuation story.
For investors, the debate is whether Thermo Fisher Scientific's current market value is fully supported by the cash flows implied by a Discounted Cash Flow (DCF) view of the business.
If you want to test the same cash flow question on a wider field, compare Thermo Fisher Scientific with 26 high quality undervalued stocks.
Has Thermo Fisher Scientific Run Too Far on Cash Flow?
The Discounted Cash Flow (DCF) approach here looks at the cash Thermo Fisher Scientific can return to shareholders over time and then discounts it back to today. Latest twelve month free cash flow sits at about $7.7b, and the model expects this to grow over the coming years rather than contract, with projected annual free cash flow moving into the low to mid teens in $ billions.
Those rising cash flow estimates still leave the DCF outcome meaningfully below the current $704.15 share price, which suggests the market is already paying a premium for Thermo Fisher Scientific's pipeline in cell and gene therapy, bioprocessing and diagnostics. The recent report highlighting Thermo Fisher Scientific's role in a fast growing proteomic biomarker analytics market helps explain why sentiment can support that premium even as the cash flow model comes out more conservative than the share price implies. Find out what Thermo Fisher Scientific could be worth using our Discounted Cash Flow (DCF) estimate.
The Thermo Fisher Scientific Narrative: What Would Justify Today's Price?
Simply Wall St Narratives pick up where the Thermo Fisher Scientific cash flow puzzle leaves off by explaining which paths for revenue, margins and earnings would need to occur for the stock to be worth meaningfully more or less than today’s share price. Each scenario focuses on the assumptions that shape its view of fair value so you can weigh those inputs against Thermo Fisher Scientific's actual results as they are reported over time on the Community page.
Thermo Fisher Scientific attracts one camp that sees more upside in the current setup and another that views the stock as largely priced in already.
Bull case: 12% undervalued
"The combination of PPD and Clario creates scope for Thermo Fisher Scientific to package data rich, AI supported clinical trial services with its existing lab products…"
Discover why this Narrative puts Thermo Fisher Scientific at 12% undervalued.
Bear case: roughly fairly valued
"Thermo Fisher Scientific is viewed as fairly valued and the current share price implies that the market already prices in continued mid-single-digit organic growth…"
Explore why this Narrative puts Thermo Fisher Scientific at roughly fairly valued.
Before acting on Thermo Fisher Scientific's valuation, there is one more piece to check
The cash flow story matters, but the people choosing where each dollar goes, how they are rewarded and what they prioritise can tilt outcomes in quiet but powerful ways. See who runs Thermo Fisher Scientific and how they are paid.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com